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Abstract
Introduction: Sodium chloride supplementation in salt-
wasting congenital adrenal hyperplasia (CAH) is generally 
recommended in infants, but its implementation in routine 
care is very heterogeneous. Objective: To evaluate oral so-
dium chloride supplementation, growth, and hydrocorti-
sone and fludrocortisone dose in infants with salt-wasting 
CAH due to 21-hydroxylase in 311 infants from the AQUAPE 
CAH database. Results: Of 358 patients with classic CAH 
born between 1999 and 2015, 311 patients had salt-wasting 
CAH (133 females, 178 males). Of these, 86 patients (27.7%) 
received oral sodium chloride supplementation in a mean 
dose of 0.9 ± 1.4 mmol/kg/day (excluding nutritional sodium 
content) during the first year of life. 225 patients (72.3%) 
were not treated with sodium chloride. The percentage of 
sodium chloride-supplemented patients rose from 15.2% in 
children born 1999–2004 to 37.5% in children born 2011–
2015. Sodium chloride-supplemented and -unsupplement-
ed infants did not significantly differ in hydrocortisone and 
fludrocortisone dose, target height-corrected height-SDS, 
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and BMI-SDS during the first 2 years of life. Conclusion: In the 
AQUAPE CAH database, approximately one-third of infants 
with salt-wasting CAH receive sodium chloride supplemen-
tation. Sodium chloride supplementation is performed more 
frequently in recent years. However, salt supplementation 
had no influence on growth, daily fludrocortisone and hy-
drocortisone dose, and frequency of adrenal crisis.
© 2017 S. Karger AG, Basel
Introduction
Congenital adrenal hyperplasia (CAH) is an autoso-
mal-recessive disorder of adrenal steroidogenesis, in 
which cortisol metabolism is impaired. 90–95% of cases 
are caused by 21-hydroxylase deficiency due to CYP21A2 
mutations [1]. 
Mineralocorticoid deficiency occurs in approximately 
75% of cases of 21-hydroxylase deficiency (salt-wasting 
CAH). Conventional treatment of CAH due to 21-hy-
droxylase deficiency consists of glucocorticoid and min-
eralocorticoid replacement [1–3]. It is generally recom-
mended that infants with salt-wasting CAH are addition-
ally treated with sodium chloride supplementation [3]. 
This recommendation is based on a study on sodium bal-
ance in 8 infants with salt-wasting CAH [4].
Clinical experience shows, that not all pediatric endo-
crinologists follow this recommendation. The aim of our 
study was to evaluate the frequency of sodium chloride 
supplementation in a large CAH cohort and to analyze its 
effect on growth and on fludrocortisone and hydrocorti-
sone dose.
Patients and Methods
The AQUAPE CAH initiative (AQUAPE: Arbeitsgemeinschaft 
für Qualitätssicherung in der pädiatrischen Endokrinologie) is 
based on a software for prospective documentation of clinical fol-
low-up data in patients with CAH. It also serves as a quality control 
procedure and contributes to a cumulative CAH research data-
base. Thirty-seven pediatric endocrine centers in Germany and 
Austria participate in AQUAPE CAH. Anonymized data are trans-
ferred annually. The data are verified and corrected at the coordi-
nating center, if necessary. Each center complied with local ethical 
and data management guidelines. All data were collected during 
routine care and the AQUAPE CAH initiative was approved by the 
local ethics committee.
Patients with classic CAH due to 21-hydroxylase deficiency 
born after 1999 were included for analysis. 358 patients with classic 
CAH (5,022 patient visits) were identified. The majority (76.0%) 
of patients was diagnosed by newborn screening (in some German 
federal states newborn screening started later than 1999). In most 
patients the diagnosis of 21-hydroxylase deficiency was confirmed 
by mutation analysis of the CYP21A2 gene and classification of 
salt-wasting CAH was supported by “severe” CYP21A2 mutations, 
homozygous gene deletions, or conversions consistent with ≤1% 
21-hydroxylase activity. Only patients with salt-wasting CAH re-
ceived sodium chloride supplementation and were included in the 
analysis. Sodium chloride dose was calculated as mmol/kg/day, 
fludrocortisone dose was calculated as µg/m2/day and hydrocorti-
sone dose was calculated as mg/m2/day. Body mass index (BMI) 
was calculated as weight in kilograms divided by the square of 
height in meters. BMI standard deviation score (BMI-SDS) was 
derived from national contemporary reference data by Kromeyer-
Hauschild et al. [5]. Height data was corrected for target height and 
is expressed as corrected height-SDS using national contemporary 
reference data [6].
Blood pressure values were compared with reference values for 
systolic and diastolic blood pressure from Flynn [7] (0–12 months 
of age). A blood pressure above the 95th centile was considered 
hypertensive.
Statistical analysis was performed with the software package 
SAS version 9.2 (Statistical Analysis Systems, SAS Inc., Cary, NC, 
USA). A p value <0.05 was considered significant (2-sided). Be-
tween-group comparisons were performed with the nonparamet-
ric Mann-Whitney U test.
Results
In total, 358 patients (153 female, 205 male) with clas-
sic CAH born after 1999 were identified in the database. 
Of these, 311 (86.9%) patients (133 female, 178 male) 
were classified as salt-wasting CAH and 47 (13.1%) pa-
tients were classified as simple virilizing CAH (20 female, 
27 male). The female-to-male ratio is unusual and might 
be explained by the combination of the neonatal screen-
ing program and a bias in patient inclusion, since not all 
German and Austrian pediatric endocrine centers par-
ticipate in AQUAPE CAH. Of 311 patients with salt-
wasting CAH, 86 (27.7%) patients were additionally 
treated with sodium chloride. In salt-wasting patients 
born between 1999 and 2004, only 15.2% of patients re-
ceived salt supplementation, whereas 34.4% of salt-wast-
ing patients born between 2005 and 2010 were addition-
ally treated with sodium chloride. In salt-wasting patients 
born between 2011 and 2016 the fraction of salt-supple-
mented patients was 37.5%.
Mean additional sodium chloride supplementation 
(without feeding/nutrition) during the first year of life 
was 0.9 ± 1.4 mmol/kg/day. After the first year of life, so-
dium chloride supplementation was discontinued in the 
vast majority of patients.
In Tables 1 and 2, the data for fludrocortisone and hy-
drocortisone dose, target height-corrected height-SDS, 
and BMI-SDS during the first 2 years of life are compared 
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between patients with and without sodium chloride sup-
plementation: patients with and without sodium chloride 
supplementation do not differ in their mean daily fludro-
cortisone or hydrocortisone dose. There was also no in-
fluence of salt supplementation on growth and BMI-SDS 
during the first 2 years of life.
Blood pressure was only measured or documented in 
the database in one-third of patients (33.3%) during the 
first year of life. Blood pressure data are shown in Table 
3. Blood pressure above the 95th centile was measured in 
13.6% of patients treated with hydrocortisone and fludro-
cortisone only and in 21.0% of patients who were addi-
tionally supplemented with sodium chloride. This differ-
ence was statistically not significant (p = 0.228). Also, no 
significant correlation between hypertension and sodium 
chloride supplementation was found. Unfortunately, 
data on renin or plasma renin activity and serum sodium 
concentrations were insufficient for a more detailed anal-
ysis. After the start of gluco- and mineralocorticoid ther-
apy, no adrenal or salt-wasting crises were reported in 
both groups during the evaluation period.
Mean target height-corrected height-SDS dropped 
from +0.7 SDS to –0.2 SDS over the study period, where-
as BMI-SDS remained relatively stable.
Discussion
In the German-Austrian AQUAPE CAH database, ap-
proximately one-third of salt-wasting CAH infants are 
supplemented with sodium chloride. A trend towards salt 
supplementation in salt-wasting CAH infants can be ob-
served in recent years, although the majority of infants 
with salt-wasting CAH are still not salt supplemented. 
Reasons for supplementing sodium chloride are the low 
nutritional content in breast milk or formula and the 
higher demand in the state of salt waste [4, 8]. Of course, 
normal plasma sodium concentrations are essential for 
regular thriving, but the question is if this can only be 
achieved in children with salt-wasting CAH by addition-
al salt supplementation during infancy or also with ad-
ministration of sufficient but not harmful doses of fludro-
cortisone. Frequently reported reasons for omitting so-
dium chloride substitution are feeding problems and 
gastrointestinal symptoms associated with salt supple-
mentation and the belief or experience that sufficient 
fludrocortisone doses are equally effective in stabilizing 
sodium concentrations and avoiding salt-wasting crises. 
Interestingly, sodium chloride supplementation had no 
significant effect on fludrocortisone dose in our cohort. 
Table 1. Comparison of fludrocortisone and hydrocortisone dose, body mass index (BMI)-SDS and target height 
(TH)-corrected height-SDS between sodium chloride-supplemented and -unsupplemented patients with salt-
wasting congenital adrenal hyperplasia (mean ± SD)
Salt supplementation
group (n = 86)
No salt supplementation
group (n = 225)
p value
Start of treatment
Fludrocortisone, µg/m2/day 442±201 376±237 0.1469
Hydrocortisone, mg/m2/day 17.7±5.2 22.0±10.3 0.1633
BMI-SDS 0.1±1.4 0.2±1.2 0.8727
TH-corrected height-SDS 0.7±1.2 0.7±1.5 0.9645
3 months
Fludrocortisone, µg/m2/day 434±213 428±230 0.8979
Hydrocortisone, mg/m2/day 18.1±4.6 18.9±8.3 0.5027
BMI-SDS –0.1±1.3 –0.2±1.6 0.6552
TH-corrected height-SDS 0.3±1.2 0.0±1.6 0.2434
1 year
Fludrocortisone, µg/m2/day 208±92 188±77 0.2093
Hydrocortisone, mg/m2/day 12.8±2.9 12.7±5.2 0.9276
BMI-SDS 0.0±1.1 0.2±1.3 0.2988
TH-corrected height-SDS –0.3±1.1 –0.5±1.2 0.4793
2 years
Fludrocortisone, µg/m2/day 130±56 116±54 0.1048
Hydrocortisone, mg/m2/day 12.1±3.1 12.0±2.9 0.8287
BMI-SDS 0.2±1.1 0.3±1.0 0.4727
TH-corrected height-SDS –0.2±1.0 –0.2±1.1 0.6152
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In both groups, fludrocortisone dose was rather high dur-
ing the first year of life, which can partially be explained 
by the relative mineralocorticoid resistance in infancy [8, 
9]. Nevertheless, fludrocortisone doses might have been 
too high especially in children with salt supplementation, 
so that no difference in true fludrocortisone needs could 
be detected.
The challenge in infants and toddlers with CAH per-
sists in finding the appropriate fludrocortisone dose in 
order to avoid life-threatening salt-wasting crises often 
Table 2. Comparison of fludrocortisone and hydrocortisone dose, body mass index (BMI)-SDS and target height 
(TH)-corrected height-SDS between sodium chloride-supplemented and -unsupplemented patients with salt-
wasting congenital adrenal hyperplasia
Salt supplementation group (n = 86) No salt supplementation 
group (n = 225)
P10 median P90 P10 median P90
Start of treatment
Fludrocortisone, µg/m2/day 217.2 420.6 850.9 176.2 400.6 877.1
Fludrocortisone, µg/day 50.0 100 200 40.0 100.0 200.0
Hydrocortisone, mg/m2/day 12.9 17.6 23.8 11.8 17.6 35.1
BMI-SDS –1.6 –0.1 1.9 –2.8 –0.4 1.1
TH-corrected height-SDS –1.2 0.1 1.9 –2.2 0.2 2.3
3 months
Fludrocortisone, µg/m2/day 223.7 336.2 629.8 169.8 320.2 509.4
Fludrocortisone, µg/day 75.0 100.0 200.0 50 100 150
Hydrocortisone, mg/m2/day 8.9 13.7 18.5 9.7 14.4 19.1
BMI-SDS –0.7 0.3 2.1 –1.1 0.3 2.0
TH-corrected height-SDS –0.7 0.6 1.8 –1.3 0.5 1.7
1 year
Fludrocortisone, µg/m2/day 109.9 204.1 315.6 110.1 180.5 263.9
Fludrocortisone, µg/day 50.0 100.0 150.0 50.0 75.0 125.0
Hydrocortisone, mg/m2/day 9.0 12.2 16.6 8.5 11.6 16.2
BMI-SDS –1.5 0.1 1.5 –1.5 0.1 1.8
TH-corrected height-SDS –2.2 –0.3 1.1 –2.0 –0.35 0.9
2 years
Fludrocortisone, µg/m2/day 79.8 112.2 202.0 48.1 100.6 179.2
Fludrocortisone, µg/day 50.0 50.0 100.0 25.0 50.0 100.0
Hydrocortisone, mg/m2/day 9.0 11.2 18.1 8.5 11.8 15.5
BMI-SDS –1.3 0.2 1.6 –1.0 0.1 1.7
TH-corrected height-SDS –1.4 –0.3 1.1 –1.4 –0.3 1.2
P10, 10th centile; P90, 90th centile.
Table 3. Blood pressure data
  Salt supplementation group No salt supplementation group
P10 median P90 P10 median P90
Systolic blood pressure, mm Hg 80 105 128 80 100 125
Diastolic blood pressure, mm Hg 49 64 82 45 63 84
n = 294 blood pressure measurements in children with salt supplementation, n = 570 blood pressure 
measurements in children without salt supplementation during the first year of life. P10, 10th centile; P90, 90th 
centile.
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triggered by minor illness and, at the same time, avoid 
fludrocortisone overdosage to prevent arterial hyper-
tension. In a single center study, 45.5% of infants had 
systolic hypertension during the first year of life and 
57.6% of 1- to 1.5-year-old infants had systolic hyper-
tension when higher fludrocortisone doses were given 
and when plasma renin activity was at the lower normal 
range or suppressed [10]. In that study, both systolic 
and diastolic blood pressure correlated with fludrocor-
tisone dose, but not with BMI. These infants were not 
supplemented with sodium chloride. Unfortunately, 
data on blood pressure and renin or plasma renin activ-
ity were incomplete in the AQUAPE CAH database for 
children younger than 3 years of age. The presented data 
on sodium supplementation in CAH infants has been 
extracted from a quality control database and therefore 
cannot completely answer complex scientific questions. 
But it is still interesting to note that the majority of Ger-
man and Austrian pediatric endocrinologists are hesi-
tant to treat CAH infants with salt and prefer higher 
fludrocortisone doses. It would be of great interest to 
compare the implementation rate of sodium replace-
ment with other countries, but such data have not been 
published so far. 
In the original study [4], on which the recommenda-
tion of salt supplementation in salt-wasting CAH is based, 
an increase in fludrocortisone dose resulted in a slight 
increase in systolic blood pressure (5–10 mm Hg) and had 
no effect on renal sodium excretion, whereas a decrease 
in plasma potassium concentration was observed. The 
calculated mean negative sodium balance on constant hy-
drocortisone (20–25 mg/m2/day) and fludrocortisone 
(150–200 µg/m2/day) replacement was 2.2 mmol/kg/day 
and ranged from 0.5 to 4.9 mmol/kg/day. With sodium 
chloride supplementation in that range, the authors were 
able to normalize plasma sodium concentrations. The au-
thors also reported that salt supplementation can be 
stopped after a few months, when precursor hormones 
such as progesterone and 17-hydroxyprogesterone with 
anti-mineralocorticoid effects have been lowered by glu-
cocorticoid replacement therapy or when more salty 
foods are given.
The reported loss in height-SDS during the first year 
of life in infants with and without salt supplementation in 
the AQUAPE CAH cohort has also been reported previ-
ously in other CAH cohorts [11, 12]. High birth length of 
CAH children might be the result of hyperandrogenism 
in utero, and glucocorticoid treatment after birth leads to 
normalization of hyperandrogenism and a decline in 
growth velocity.
In a longitudinal analysis of growth and puberty in 
21-hydroxylase-deficient patients, Van der Kamp et al. 
[13] compared growth and final height of 17 salt-supple-
mented salt-wasting CAH patients to 17 salt-wasting 
CAH patients without salt supplementation. Salt supple-
mentation was given between 0.19 and 0.9 years in a mean 
dose of 2.5 mmol/kg/day. The fludrocortisone dose be-
tween the two groups was comparable, but the hydrocor-
tisone dose was significantly higher in the salt supple-
mentation group. Mean length-SDS at 2 years was higher 
in the salt-supplemented group (–1.0 SDS vs. –1.56 SDS) 
and final height corrected for target height was also high-
er in the salt-supplemented group (–0.83 SDS vs. –1.69 
SDS). In a multiple regression analysis, final height-SDS 
showed a positive correlation with salt supplementation 
during the first year of life in patients with salt-wasting 
CAH. In that study, also, no data on blood pressure, re-
nin, or plasma renin activity was analyzed.
In summary, in the AQUAPE CAH database, approx-
imately only one-third of infants with salt-wasting CAH 
receive sodium chloride supplementation. Sodium chlo-
ride supplementation is performed more frequently in re-
cent years. However, salt supplementation had no influ-
ence on growth and daily fludrocortisone and hydrocor-
tisone dose in a cohort that received relatively high 
fludrocortisone doses during the first year of life.
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